© 2018 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

Treatment News

U.S. Should Aim to Suppress HIV Within 3 Months of Diagnosis
Cognitive Behavioral Therapy Helps HIV-Positive Smokers Quit
Among Pregnant Women With HIV, Hep C Is Tied to Preterm Delivery

Reports of Imminent HIV Cure, Once Again, Are False

The latest collection of articles stems from a tiny study in Uganda, neither peer-reviewed nor presented at a conference.

Switching to New Tenofovir Is Tied to Higher LDL Cholesterol

Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.

Trogarzo Can Keep Viral Load Suppressed for at Least a Year

Researchers gave the antibody treatment to those with multidrug-resistant HIV along with an optimized antiretroviral regimen.

Gilead’s Biktarvy Is as Effective as Tivicay Plus Descovy

Biktarvy has a lower rate of adverse health events, according to 96-week data.

Smoking Is Tied to Faster Lung Function Decline in People With HIV

This finding comes from the global START study that in 2015 proved that starting HIV treatment early is preferable to delaying.

MUST read

Another Study Shows No HIV Transmission From Undetectable Partners
Atripla
It May Be Possible to Take Atripla Just Three Times a Week
There’s Never Been a Better Time to Get Pregnant If One of You Has HIV

Self-Lubricating Condom Shows Promise in Early Study

The condom’s coating absorbs water.

More Good Marks for Janssen’s New HIV Regimen Symtuza

Researchers have presented 96-week results from an advanced trial of Symtuza compared with Prezcobix plus Truvada.

Hepatitis C Increases Risk of Death Among People on HIV Treatment

Treating hep C lowers the risk.

Two-Drug Protease Inhibitor–Based HIV Regimens Are Safe and Effective

Among those taking Epivir, taking two antiretrovirals instead of three was tied to fewer people stopping because of side effects.

ViiV’s Long-Acting Injectable HIV Regimen Boasts Good 3-Year Results

The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.

Hot topics

#Cure
#Long-Term Survivors
Ounce of Prevention sign against a blue sky
#Prevention
PrEP written on a chalkboard
#PrEP
HPV vaccine

Latinos With HIV Are at Higher Risk of HPV-Related Cancers

In particular, women have a higher risk of cervical cancer and men have a higher risk of anal cancer.

Switching to New Version of Antiretroviral Tenofovir May Lead to Weight Gain

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.

HIV Vaccine Experts Sketch Road Map for Research

The Global HIV Vaccine Enterprise hopes to hasten the development of a safe and effective vaccine against the virus.

Long-Acting HIV Meds Are in the Works, but Do People Want Them?

Researchers polled people on HIV treatment about their preferences for various forms of long-acting antiretrovirals.
Advertisement
Newsfeed
Features
Opinions
POZ Stories

Hot topics

Forums: Support and discussion
Blogs: The community speaks
POZ Stories: Get inspired
Magazine: Search the archives
HIV: The Basics
Recursos de VIH/SIDA en Español
AIDS Is Everyday
Ask POZ